Could This $198 Million IPO Become the Next Eli Lilly in Weight Loss Innovation?

Listen, I know we’ve talked about diabetes drugs that double as weight-loss wonders so much you’re probably sick of it. But before you click away and start researching tech stocks to YOLO into, let’s give credit where it’s due—Eli Lilly and Novo Nordisk are cashing in big time. Their stocks have soared 728% and 361% over the last five years, making investors as excited as my kids seeing a Build-A-Bear.

Now meet BioAge Labs, the latest name shaking up the weight-loss industry. Fresh off a $198 million IPO, this company is gaining attention faster than that creepy Halloween skeleton in your neighbors front lawn. They’re stepping into the ring with some serious science behind them, and investors are starting to sweat (in a good way).

So, what’s BioAge bringing to the table? Their star player, azelaprag, is a pill that mimics a hormone released during exercise. It’s like having a personal trainer who actually brings you snacks and doesn’t yell at you for skipping leg day. Early trials suggest that combining azelaprag (try to say that three times) with those GLP-1 injections might actually help you shed pounds while keeping your muscles intact. 

What’s more, BioAge is rolling out clinical trials fast.They’re testing azelaprag alongside Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide. If they can prove that their pill can make those injections even more effective, BioAge will have a market as large as the two leading medicines on the market right now.  

That's why Morgan Stanley analysts are practically drooling over the potential here, stating that the market for these GLP-1 drugs is poised to be a $105 billion market by 2030. 

BioAge Labs isn’t stopping at weight loss—they’re going full “Benjamin Button”, aiming to help you live longer and feel great doing it. The claims are that azelaprag flips the switch on a cellular receptor called APJ. This little receptor could be the key to increasing your metabolism, keeping your muscles strong, and maybe even adding a few more candles to your birthday cake, all while making aging a little less of a drag.

But, is BioAge really the next Eli Lilly? Let’s chill for a sec. Eli Lilly is already sitting high on biotech mountain, while BioAge is still wandering around the lobby, trying to find the coat check. Let’s see if they can handle the spotlight before we start handing out crowns. That said, if you’re the type who likes a little thrill in your portfolio, snatching up shares of BioAge makes a lot of sense. And their shares are already up 21% in less than 2 weeks. 

P.S. I won't sugar coat this, but if you haven't been paying attention, we are on the brink of what many are calling the next cycle of a raging bull market, and with our last alert skyrocketing up 53% last week - our next alert on Thursday could be the one trade that kicks this whole cycle off. Now I won't go to much into the specifics, but here's the thing, we've successfully predicted up to 16 triple-digit (100% or more) opportunities nearly every single week for the past four months... and the one we are eyeing on Thursday is set to one of the most storied setups of the year. Meaning, if you haven't done so yet, I'd highly suggest clicking here ASAP before sh^t really does hit the fan later this week. Don't say I didn't warn ya!

Stock.News has positions in Netflix, Eli Lilly, Novo Nordisk, Morgan Stanley, and Build-A-Bear.